Mode of prostate cancer detection is associated with the psychological wellbeing of survivors: results from the PiCTure study

Show simple item record

dc.contributor.author Drummond, Frances J.
dc.contributor.author O'Leary, Eamonn
dc.contributor.author Gavin, Anna T.
dc.contributor.author Kinnear, Heather
dc.contributor.author Linda, Sharp
dc.date.accessioned 2019-10-26T07:13:57Z
dc.date.available 2019-10-26T07:13:57Z
dc.date.issued 2015-11-23
dc.identifier.citation Drummond, F. J., O’Leary, E., Gavin, A., Kinnear, H. and Sharp, L. (2016), 'Mode of prostate cancer detection is associated with the psychological wellbeing of survivors: results from the PiCTure study', Supportive Care in Cancer, 24(5), pp. 2297-2307. DOI: 10.1007/s00520-015-3033-x en
dc.identifier.volume 24 en
dc.identifier.issued 5 en
dc.identifier.startpage 2297 en
dc.identifier.endpage 2307 en
dc.identifier.issn 0941-4355
dc.identifier.uri http://hdl.handle.net/10468/8881
dc.identifier.doi 10.1007/s00520-015-3033-x en
dc.description.abstract Purpose: Many men with prostate cancer are asymptomatic, diagnosed following prostate specific antigen (PSA) testing. We investigate whether mode of detection, i.e. ‘PSA detected’ or ‘clinically detected’, was associated with psychological wellbeing among prostate cancer survivors. Methods: A cross-sectional postal questionnaire was administered in 2012 to 6559 prostate cancer (ICD10 C61) survivors up to 18 years post-diagnosis, identified through population-based cancer registries in Ireland. Psychological wellbeing was assessed using the Depression Anxiety Stress Scale-21. Logistic regression was used to investigate associations between mode of detection and depression, anxiety and stress, adjusting for socio-demographic and clinical confounders. Results: The response rate was 54 % (3348/6262). Fifty-nine percent of survivors were diagnosed with asymptomatic PSA-tested disease. Prevalence of depression (13.8 vs 20.7 %; p < 0.001), anxiety (13.6 vs 20.9 %; p < 0.001) and stress (8.7 vs 13.8 %; p < 0.001) were significantly lower among survivors diagnosed with PSA-detected, than clinically detected disease. After adjusting for clinical and socio-demographic factors, survivors with clinically detected disease had significantly higher risk of depression (odds ratio (OR) = 1.46 95 % CI 1.18, 1.80; p = 0.001), anxiety (OR = 1.36 95 % CI 1.09, 1.68; p = 0.006) and stress (OR = 1.43 95 % CI 1.11, 1.85; p = 0.006) than survivors with PSA-detected disease. Conclusions: These findings contribute to the ongoing debate on benefits and risks of PSA testing and may be considered by policy makers formulating population-based prostate cancer screening policies. The relatively high prevalence of negative psychological states among survivors means that a ‘risk-adapted approach’ should be implemented to screen survivors most at risk of psychological morbidity for psychological health, and mode of detection could be considered as a risk stratum. en
dc.description.sponsorship Health Research Board (HRA_HSR/2010/17); Prostate Cancer UK (NI09-03); en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Spring Berlin Heidelberg en
dc.relation.uri https://link.springer.com/article/10.1007%2Fs00520-015-3033-x
dc.rights ©The Author(s) 2015. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. en
dc.rights.uri http://creativecommons.org/licenses/by/4.0/ en
dc.subject Prostate cancer en
dc.subject Depression en
dc.subject Anxiety en
dc.subject Stress en
dc.subject Prostate specific antigen en
dc.subject PSA en
dc.subject Screening en
dc.title Mode of prostate cancer detection is associated with the psychological wellbeing of survivors: results from the PiCTure study en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother Frances Drummond, Cork Cancer Research Centre, University College Cork, Cork, Ireland. +353-21-490-3000. Email: frances.drummond@ucc.ie en
dc.internal.availability Full text available en
dc.description.version Published Version en
dc.contributor.funder Health Research Board en
dc.contributor.funder Prostate Cancer UK en
dc.contributor.funder National Cancer Control Programme en
dc.contributor.funder Public Health Agency en
dc.description.status Peer reviewed en
dc.identifier.journaltitle Supportive Care in Cancer en
dc.internal.IRISemailaddress frances.drummond@ucc.ie en
dc.identifier.eissn 1433-7339


Files in this item

This item appears in the following Collection(s)

Show simple item record

©The Author(s) 2015. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. Except where otherwise noted, this item's license is described as ©The Author(s) 2015. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement